IL1RAP Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated from the human Jurkat T lymphocyte cell line, providing a loss-of-function model for investigating interleukin-1 receptor accessory protein (IL1RAP).
The Jurkat cell line, derived from acute T cell leukemia, is a well-established model for T cell signaling and leukemia studies. These immortalized cells are widely used in immunological research due to their reproducible signaling properties and ease of genetic manipulation.
IL1RAP serves as a co-receptor for IL-1 and IL-33, forming heterodimers with IL-1R1 or ST2 to recruit MYD88, IRAK1, and IRAK4, which activate TRAF6-dependent signaling cascades. This triggers NF-??B and MAPK/ERK pathways, leading to transcription of pro-inflammatory genes. Upstream, IL1RAP expression is regulated by IL-1??, TNF-??, and LPS through NF-??B and AP-1. Downstream targets include NF-??B-driven IL6, IL8, and PTGS2, as well as ERK-responsive MMP9 and CXCL1. Key interacting partners of IL1RAP include IL-1R1, IL-1??, IL-1??, IL-33, ST2, MYD88, IRAK1, IRAK4, and TRAF6, positioning it as a central mediator of inflammatory signaling.
In the Jurkat T cell context, IL1RAP knockout enables dissection of IL-1/IL-33 signaling in a leukemic background, where IL1RAP overexpression is linked to acute myeloid leukemia and inflammatory disorders such as rheumatoid arthritis and Schnitzler syndrome. This model helps clarify how IL1RAP contributes to T cell inflammatory responses and leukemogenic NF-??B and MAPK signaling, offering a tractable system to study pathological mechanisms and test therapeutic interventions.
Specific applications range from mechanistic investigation of IL-1 and IL-33 signaling cascades to high-throughput screening of anti-IL1RAP antibodies or small-molecule inhibitors. The polyclonal knockout population can be used in assays measuring NF-??B activation through luciferase reporters, quantifying IL-6 and IL-8 secretion by ELISA, assessing phospho-p65 and phospho-ERK levels by immunoblotting or flow cytometry, performing cell viability assays under IL-1 stimulation, and analyzing protein-protein interactions via co-immunoprecipitation of IL1RAP with IL-1R1. For further details and technical support, please contact Ascent Research.
